Overview

YM443 in Subjects With Functional Dyspepsia

Status:
Completed

Trial end date:
2006-03-11

Target enrollment:

Participant gender:

Summary

The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Astellas Pharma US, Inc.

Treatments:

Z 338